Ed Ahn, CEO of MEDIPOST, is developing next-generation stem cell therapies for inflammation-driven degenerative diseases with a primary focus on knee osteoarthritis. Using umbilical cord-derived stem cells, which have higher proliferation capacity than adult-derived stem cells, allows MEDIPOST to scale cell manufacturing and provide broader access to care. The company's lead program, Cartistem, has been approved in Korea for over 10 years, and new funding will accelerate US clinical trials.

Ed explains, "We are focused on treating inflammation-driven degenerative diseases. So all these diseases that you commonly associate with the aging process. Those are some of the things that we're very interested in slowing the progression of."

"We're actually going back to the source for neonatal stem cells from the cord blood. One of the primary advantages of going for a neonatal source of stem cells versus an adult source is that these are the most naive stem cells that one can obtain. And what I mean by naive is that they've been in a protected environment in the mother's womb. They have not been exposed to a lot of the different antigens that adults have been exposed to. So they're very immune-privileged compared to adult stem cells."

"I think this idea or the concern about cost can be applied to all sorts of regenerative medicines, whether or not they're gene therapies or cell therapies, they're amongst the most expensive therapies to manufacture for a company, primarily because we're building a process around an inherently biological process.

One of the advantages we have at MEDIPOST is that this product has been approved in Korea for over 10 years. So we have a tremendous amount of manufacturing experience and know-how from our parent company in Korea that we're able to apply to our manufacturing process in North America. And that really advances and matures our program far beyond other people in the field."

#MEDIPOST #CARTISTEM #StemCellTherapy #KneeOsteoarthritis #RegenerativeMedicine #Innovation #Healthcare #Biotech #ClinicalTrials #JointHealth #AntiAging #MedicalBreakthrough #BiotechInnovation

medipost.com

Listen to the podcast here